Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

Maloney, 1994, Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma., Blood., 84, 2457, 10.1182/blood.V84.8.2457.2457 McLaughlin, 1998, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program., J Clin Oncol., 16, 2825, 10.1200/JCO.1998.16.8.2825 Maloney, 1997, IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma., Blood., 90, 2188, 10.1182/blood.V90.6.2188 Hainsworth, 2000, Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma., Blood., 95, 3052, 10.1182/blood.V95.10.3052 Colombat, 2001, Rituximab (anti-CD20 monoclonal antibody) as first-line therapy of follicular lymphoma patients with low tumor burden: clinical and molecular evaluation., Blood., 97, 101, 10.1182/blood.V97.1.101 Coiffier, 1998, Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study., Blood., 92, 1927 Foran, 2000, European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma., J Clin Oncol., 18, 317, 10.1200/JCO.2000.18.2.317 Anderson, 1997, Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma., Biochem Soc Trans., 25, 705, 10.1042/bst0250705 Vose, 1999, Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate or high-grade non-Hodgkin's lymphoma (NHL)., Ann Oncol., 10, 58a Berinstein, 1998, Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non- Hodgkin's lymphoma., Ann Oncol., 9, 995, 10.1023/A:1008416911099 Harjunpaa, 2000, Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms., Scand J Immunol., 51, 634, 10.1046/j.1365-3083.2000.00745.x Reff, 1994, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20., Blood., 83, 435, 10.1182/blood.V83.2.435.435 Idusogie, 2000, Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc., J Immunol., 164, 4178, 10.4049/jimmunol.164.8.4178 Golay, 2000, Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis., Blood., 95, 3900, 10.1182/blood.V95.12.3900 Shan, 1998, Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies., Blood., 91, 1644, 10.1182/blood.V91.5.1644 Shan, 2000, Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells., Cancer Immunol Immunother., 48, 673, 10.1007/s002620050016 Hooijberg, 1995, Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2., Cancer Res., 55, 2627 Funakoshi, 1996, Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas., J Immunother Emphasis Tumor Immunol., 19, 93, 10.1097/00002371-199603000-00002 Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets., Nat Med., 6, 443, 10.1038/74704 Fijen, 2000, The role of Fcγ receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals., Clin Exp Immunol., 120, 338, 10.1046/j.1365-2249.2000.01208.x Dijstelbloem, 1999, Fcγ receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse., Arthritis Rheum., 42, 1823, 10.1002/1529-0131(199909)42:9<1823::AID-ANR5>3.0.CO;2-X Myhr, 1999, Immunoglobulin G Fc-receptor (FcγR) IIA and IIIB polymorphisms related to disability in MS., Neurology., 52, 1771, 10.1212/WNL.52.9.1771 Koene, 1997, Fc γRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc γRIIIa, independently of the Fc γRIIIa-48L/R/H phenotype., Blood., 90, 1109, 10.1182/blood.V90.3.1109 Wu, 1997, A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease., J Clin Invest., 100, 1059, 10.1172/JCI119616 Sondermann, 2000, The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc γRIII complex., Nature., 406, 267, 10.1038/35018508 Harris, 1994, A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group., Blood., 84, 1361, 10.1182/blood.V84.5.1361.1361 Brice, 1997, Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte., J Clin Oncol., 15, 1110, 10.1200/JCO.1997.15.3.1110 Cheson, 1999, Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group., J Clin Oncol., 17, 1244, 10.1200/JCO.1999.17.4.1244 Jiang, 1996, Rapid detection of the Fc γ RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED)., J Immunol Methods., 199, 55, 10.1016/S0022-1759(96)00164-0 Kaplan, 1958, Nonparametric estimation from incomplete observations., J Am Stat Assoc., 53, 457, 10.1080/01621459.1958.10501452 de Haas, 1996, A triallelic Fc γ receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc γ RIIIa., J Immunol., 156, 3948, 10.4049/jimmunol.156.8.2948 Peltz, 1989, Human Fc γ RIII: cloning, expression, and identification of the chromosomal locus of two Fc receptors for IgG., Proc Natl Acad Sci U S A., 86, 1013, 10.1073/pnas.86.3.1013 Schnackenberg, 1997, Linkage disequilibria between Duffy blood groups, Fc γ IIa and Fc γ IIIb allotypes., Exp Clin Immunogenet., 14, 235 Shields, 2001, High resolution mapping of the binding site on human IgG1 for Fc γ RI, Fc γ RII, Fc γ RIII, and FcRn and design of IgG1 variants with improved binding to the Fc γ R., J Biol Chem., 276, 6591, 10.1074/jbc.M009483200 Leppers-van de Straat, 2000, A novel PCR-based method for direct Fcγ receptor IIIa (CD16) allotyping., J Immunol Methods., 242, 127, 10.1016/S0022-1759(00)00240-4 Lehrnbecher, 1999, Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations., Blood., 94, 4220, 10.1182/blood.V94.12.4220